Avricore Health (AVCR) AI Stock Analysis

• Market Cap: $7.09M
• Dividend Yield: N/A
• Average Volume (3M): 68.54K
• Price to Earnings (P/E): 63.6
• Beta (1Y): 0.47
• Revenue Growth: -31.23%
• EPS Growth: N/A
• Country: CA
• Employees: 2
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): >-0.01
• Shares Outstanding: 101,289,665
• 10 Day Avg. Volume: 62,544
• 30 Day Avg. Volume: 68,543
• PEG Ratio: 1.92
• Price to Book (P/B): 2.80
• Price to Sales (P/S): 1.15
• P/FCF Ratio: 6.90
• Enterprise Value/Market Cap: 0.59
• Enterprise Value/Revenue: 1.36
• Enterprise Value/Gross Profit: 3.17
• Enterprise Value/Ebitda: -13.13
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 64 Neutral
• Price Target: ―

Avricore Health's strong financials and strategic corporate developments are offset by high valuation concerns and neutral technical indicators. The company's financial stability and growth potential are promising, but profitability and valuation require attention.

Avricore Health Business Overview & Revenue Model

Company Description

Avricore Health Inc. engages in the health data and point-of-care technologies business in Canada. It provides HealthTab, a lab-accurate point of care testing platform for pharmacy. The company has strategic partnerships with Shoppers Drug Marts and Abbott. The company was formerly known as Vanc Pharmaceuticals Inc. and changed its name to Avricore Health Inc. in October 2018. Avricore Health Inc. was founded in 1996 and is based in Vancouver, Canada.

How the Company Makes Money

Avricore Health generates revenue through the sale and deployment of its HealthTab platform in partnership with pharmacies and healthcare providers. The company earns money by charging fees for each test conducted on its platform and through subscription models that allow pharmacies to access and utilize the HealthTab technology. Additionally, Avricore Health benefits from strategic partnerships with leading diagnostic and pharmaceutical companies, which may provide funding or revenue-sharing opportunities to further expand its market presence. The company's revenue model is heavily reliant on the adoption of its technology by healthcare networks and the volume of diagnostic tests performed.

Avricore Health Financial Statement Overview

Summary

Avricore Health demonstrates robust financial performance with strong revenue growth and operational efficiency. The balance sheet is solid with no debt, and cash flow management is improving. However, profitability remains an area for enhancement.

Income Statement

Avricore Health has shown significant improvement in its revenue, with a notable growth rate of 35.42% from the previous year. The company's gross profit margin stands at 37.94%, indicating strong cost management. However, the net profit margin is relatively low at 2.18%, which suggests room for improvement in profitability. Nevertheless, the positive trend in EBIT and EBITDA margins reflects a trajectory towards operational efficiency.

Balance Sheet

The balance sheet of Avricore Health is robust, with a strong equity ratio of 82.29%, indicating a solid financial foundation. The company has no debt, reflected in a debt-to-equity ratio of 0, which significantly reduces financial risk. Return on equity is positive at 4.14%, demonstrating effective utilization of shareholders' equity.

Cash Flow

Avricore Health's cash flow position is improving, with a strong operating cash flow to net income ratio of 8.78, indicating efficient cash management relative to earnings. The free cash flow to net income ratio is 3.41, showing a positive trend in generating free cash flow. The company has successfully shifted from negative to positive free cash flow growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.08M	4.79M	3.49M	1.77M	122.81K	33.03K
Gross Profit	1.32M	1.88M	1.20M	456.79K	30.52K	17.48K
EBITDA	-319.72K	-208.44K	-275.14K	-629.76K	-1.64M	-930.40K
Net Income	-1.43M	-668.98K	-701.22K	-818.23K	-1.71M	-1.17M
Balance Sheet
Total Assets	1.67M	2.30M	2.54M	2.57M	2.28M	440.09K
Cash, Cash Equivalents and Short-Term Investments	865.19K	1.14M	286.57K	630.53K	2.01M	302.71K
Total Debt	0.00	0.00	40.00K	40.00K	40.00K	1.00M
Total Liabilities	46.55K	330.82K	529.22K	604.89K	84.48K	1.15M
Stockholders Equity	1.62M	1.97M	2.01M	1.96M	2.20M	-714.04K
Cash Flow
Free Cash Flow	230.39K	799.27K	-386.46K	-1.64M	-1.37M	-1.22M
Operating Cash Flow	399.26K	1.00M	660.40K	-437.83K	-1.23M	-1.22M
Investing Cash Flow	-168.87K	-205.35K	-1.05M	-1.21M	-140.36K	0.00
Financing Cash Flow	70.00K	56.60K	42.50K	253.88K	3.08M	1.51M

Avricore Health Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.07
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:AVCR, the sentiment is Positive. The current price of 0.07 is above the 20-day moving average (MA) of 0.07, below the 50-day MA of 0.07, and above the 200-day MA of 0.06, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 52.16 is Neutral, neither overbought nor oversold. The STOCH value of 86.67 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:AVCR.

Avricore Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AVCR	64 Neutral	$7.09M	63.64	-71.97%	―	-31.23%	―
HLS	53 Neutral	C$177.04M	-8.55	-27.55%	―	-1.42%	35.15%
GUD	47 Neutral	C$590.95M	1,744.12	0.05%	―	13.82%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Avricore Health Corporate Events

Avricore Health Enhances UK Healthcare with HealthTab-PKB Integration

Avricore Health Inc. has successfully integrated its HealthTab™ platform with Patients Know Best (PKB), the UK’s leading patient personal health record, enhancing data accessibility across healthcare providers and patients. This collaboration supports the UK’s shift towards community-based, preventative healthcare, allowing for seamless integration of pharmacy point-of-care testing results into personal health records, ultimately improving patient outcomes and empowering healthcare teams with comprehensive health data.

Avricore Health Reports Revenue Surge and UK Expansion

Avricore Health Inc. reported a significant rise in revenues and profitability for the third quarter of 2024, with a 58% year-over-year revenue increase. The company is strategically expanding its HealthTab™ services in the UK, capitalizing on the region’s strong investment in pharmacy-led healthcare services.

Avricore Health Shifts Focus to UK Market

Avricore Health has announced a strategic pivot to focus on the growing UK healthcare market, concluding its partnership with Canada’s Shoppers Drug Mart. This move is backed by the significant NHS investment in pharmacy services, which presents a larger opportunity for their HealthTab™ platform. The company maintains a strong cash position to support this expansion and has already initiated deployment in London.